Extracellular vesicles and ctDNA in lung cancer: biomarker sources and therapeutic applications.

Related Articles

Extracellular vesicles and ctDNA in lung cancer: biomarker sources and therapeutic applications.

Cancer Chemother Pharmacol. 2018 Jun 08;:

Authors: Huang C, Liu S, Tong X, Fan H

Abstract
Lung cancer is the leading cause of cancer death in the world. Recently, targeted therapy and anti-programmed cell death receptor 1 (PD-1) and anti-programmed cell death ligand 1 (PD-L1) immunotherapy have made great progress in treatment of lung cancer. However, responses to these therapies are variable, influenced by genetic alterations, high microsatellite instability and mismatch repair deficiency. Liquid biopsy of extracellular vesicles and circulating tumor DNA (ctDNA) emerges as a new promising non-invasive means that enables not only biomarker determination, but also continuous monitoring of cancer treatment. Notably, tumor extracellular vesicles play important roles in tumor formation and progression, and also serve as natural carriers for anti-tumor drugs and short-interfering RNA. In this review, we summarize the latest progress in understanding the relationships of extracellular vesicles and ctDNA in cancer biology, diagnosis and drug delivery. In particular, the application of extracellular vesicles and ctDNA in anti-PD-1/PD-L1 immunotherapy is discussed.

PMID: 29948020 [PubMed - as supplied by publisher]

https://ift.tt/2yRSOke